Overcoming cancer drug resistance


More about resistance

Cancer drug resistance



Financial reports

Financial Reports

Learn more about our unique first-in-class lead compound SCO-101

Positive topline Phase IIa data

Positive topline Phase IIa data from the CORIST part 3 trial


A great place to work

For talented, ambitious individuals who share our passion for science and drug development, we offer an exciting work environment, along with the opportunity to make a difference for the many cancer patients in need for novel treatments

Read more